In the clinical treatment of tumors, immune checkpoints (for instance, CTLA-4, TIM-3, LAG-3, and most importantly, PD-1/PD-L1) have been demonstrated to be effective targets in cancer immunotherapy due to the ability thereof to regulate immune responses (10). This evidence concerns the gene CD274 and cancer.